National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Meropenem/vaborbactam (Vaborem®) is indicated for the treatment of the following infections in adults:

  • Complicated urinary tract infection (cUTI), including pyelonephritis
  • Complicated intra-abdominal infection (cIAI)
  • Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).
  • Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
  • Vaborem® is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.
NCPE Assessment Process Complete
Rapid review commissioned 17/02/2020
Rapid review completed 02/04/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of meropenem-vaborbactam compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.